|
C6ORF170 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63347113613099E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.70863323489812E-13 |
| Normal-vs-Stage3 |
1.62581059726108E-12 |
| Normal-vs-Stage4 |
4.44089209850063E-16 |
| Stage1-vs-Stage2 |
1.604770E-01 |
| Stage1-vs-Stage3 |
7.163900E-02 |
| Stage1-vs-Stage4 |
1.404040E-02 |
| Stage2-vs-Stage3 |
8.338600E-01 |
| Stage2-vs-Stage4 |
5.719600E-01 |
| Stage3-vs-Stage4 |
3.556600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.36557432028894E-14 |
| Normal-vs-AfricanAmerican |
1.42870000052753E-07 |
| Normal-vs-Asian |
1.0429990204841E-11 |
| Caucasian-vs-AfricanAmerican |
6.474400E-01 |
| Caucasian-vs-Asian |
8.532200E-01 |
| AfricanAmerican-vs-Asian |
7.866600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62470037423645E-12 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
3.713800E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
5.55111512312578E-15 |
| Normal-vs-Age(61-80Yrs) |
1.33226762955019E-15 |
| Normal-vs-Age(81-100Yrs) |
3.91990000003783E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.739240E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.230300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.065400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.238800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.660200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.504800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.147800E-02 |
| Classical-VS-Follicular |
2.255600E-02 |
| Classical-VS-Other |
1.750980E-01 |
| Classical-VS-Normal |
2.45115039376742E-12 |
| Tall-VS-Follicular |
8.470600E-01 |
| Tall-VS-Other |
6.274400E-01 |
| Tall-VS-Normal |
3.09530179265494E-13 |
| Follicular-VS-Other |
6.052600E-01 |
| Follicular-VS-Normal |
1.62447832963153E-12 |
| Other-VS-Normal |
4.3703000000006E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
4.65183447317941E-14 |
| N0-vs-N1 |
6.158000E-01 |
|
|
